• Targeting glutamine metabolism is a novel means of treating ovarian cancer and inhibiting cancer induced ascites
Introduction

Results
Targeting glutamine using JHU-083 reduces tumor growth and progression of ascites
Objectives
Summary & Conclusion
• Together with the Johns Hopkins Drug Discovery Program, we developed a novel prodrug of 6-Diazo-5-oxo-l-norleucine (DON), to inhibit glutamine metabolism (JHU-083).
• Inhibition of glutamine metabolism blocks the generation and recruitment of MDSC within the primary breast tumor microenvironment as well as at sites of metastasis thus markedly inhibiting the development of metastatic foci.
We hypothesized that glutamine antagonism might inhibit the development of ascites and enhance anti-tumor immunity in ovarian cancer.
Abstract
Malignant ascites in ovarian cancer develops in the setting of recurrent and advanced metastatic disease and is associated with poor prognosis. Emerging evidence has demonstrated that ovarian cancer patients have altered metabolism and an immunosuppressive environment in the ascites fluid. Inasmuch as the rapid proliferation of ovarian cancer cells and development of ascites is dependent on glutamine metabolism, we hypothesized that targeting the glutamine metabolism can inhibit the development of ascites and enhance anti-tumor immunity in ovarian cancer. To test this hypothesis, we developed a novel small molecule glutamine antagonist (prodrug of 6-Diazo-5-oxo-lnorleucine, JHU-083). By employing JHU-083, we evaluated this hypothesis in mice bearing an aggressive and metastatic ovarian cancer (ID8 cell line with an overexpression of Defb29 and Vegfa). Targeting glutamine metabolism led to markedly reduced progression of ascites along with reduced tumor cell numbers. Furthermore, JHU-083 treatment also led to a marked diminution of the volume of fluid in mice with already established ascites. Inhibition of glutamine metabolism also led to a less suppressive tumor microenvironment by blocking the recruitment of myeloid derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) to the ascites fluid. Functionally, both the TAMs and tumor cells from the JHU-083 treated group showed lower expression of PDL1 compared to the vehicle treated group. Additionally, we also observed reduced regulatory T cell (T regs) percentages and numbers with JHU-083 treatment. These findings are consistent with our previous observations that targeting glutamine metabolism can inhibit the generation and recruitment of MDSC and T regs by targeting both tumor cell and immune cell metabolism. Further, LC-MS based metabolite analysis of the ovarian cancer ascites fluid from JHU-083 treated mice revealed distinct differences in urea-ornithine pathway, nucleotide synthesis, and redox balance related metabolites. In light of these findings, ongoing experiments are examining the efficacy of JHU-083 in combination with epigenetic drugs, VEGF inhibitors, PARP inhibitors, and checkpoint blockade. These studies suggest that targeting glutamine metabolism may represent a novel approach to treating metastatic ovarian cancer and ascites.
Glutamine antagonism reduces suppressive microenvironments for T cell proliferation 
Glutamine antagonism changes metabolic TMEs in ascites fluids
Targeting glutamine using JHU-083 markedly reduces PDL1 expression on ovarian cancer cells and TAMs 
DON 5uM
Vehicle JHU083
